From the article: Alseres Pharmaceuticals, Inc. announced that on April 15, 2008, Dr. Mark Hurtt, Chief Medical Officer, will discuss the CETHRIN development program as a member of an expert panel on Spinal Cord Injury Research during a congressional briefing on Capitol Hill focused on “Rapid Advancements in Paralysis Research.” In addition, Dr. Hurtt will present interim results of the CETHRIN Phase I/IIa clinical trial in acute spinal cord injury during a plenary session on April 13, 2008 at the “Working 2 Walk” Science and Education Symposium in Washington, DC. Read more here.
Posted on